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Introduction
Worldwide alcohol causes 2.5 million deaths per year (World 
Health Organisation, 2011) whilst tobacco is implicated in twice 
this number (Mackay et al., 2006), collectively accounting for 
12% of all deaths. The health costs of tobacco smoking total $96 
billion per year in the USA and £2.25 billion in the UK (Mackay 
et al., 2006). The cost of alcohol is an accumulation of health, 
social and crime-related spending and can total up to £20 billion 
in the UK and $200 billion in the USA (Global Status Report on 
Alcohol and Health, 2011). Recently, there has been an increase in 
non-medical use of prescription analgesics (or painkillers), with a 
growing trend of ‘pill mills’ and ‘doctor shopping’. In the USA, 
the non-medical use of these drugs by 12 million people made 
them the second most common form of illicit drug use after can-
nabis in 2010 (Substance Abuse and Mental Health Services 
Administration, 2011). Deaths from prescription analgesics in the 
USA are greater than those from heroin and cocaine combined, 
with rates tripling in the last 10 years (Centre for Disease Control 
and Prevention, 2011), which is perhaps unsurprising given their 
much larger number of consumers.
Illicit drugs are only used by a minority of the world’s popula-
tion, with between 3.5% and 5.7% having used an illicit substance 
at least once (United Nations Office on Drugs and Crime, 2010). 
Around 10–15% of these are classed as ‘problematic users’. 
Cannabis has the highest prevalence of use followed by ampheta-
mine, cocaine and heroin. In the UK, problem drug use of Class A 
substances costs society £15.4 billion a year, of which £13.9 bil-
lion is attributable to criminal offences. The US Department of 
Justice National Drugs Intelligence Centre (2011) reported that 
the total impact of illicit substances on society amounted to over 
$193 billion, with crime and incarceration accounting for over 
$100 billion of these costs.
Current approaches aimed at reducing illicit drug use include 
prohibition of supply, education and treatment. Most countries 
and international agencies (such as the United Nations and World 
Health Organisation), classify drugs according to how dangerous 
or harmful they are. For example, under the UK Misuse of Drugs 
Act 1971, drugs are segregated into three classes (A, B and C) 
which are meant to (i) reflect their relative harms and (ii) deter-
mine the penalties for possessing and trafficking each drug. In the 
USA drugs are classified into five schedules reflecting their 
‘potential for abuse’. It has been argued that these systems have 
evolved in an unsystematic way according to social, political and 
historical concerns rather than being based on any scientific 
evidence.
Recently, attempts have been made to develop a ‘rational’ 
scale to assess and compare the overall harms of psychoactive 
drugs (Nutt et al., 2007). Their ‘harm matrix’ included three 
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categories of harm: ‘physical’, ‘dependence-related’ and ‘social’, 
each with three sub-levels, allowing currently used and new psy-
choactive substances to be more objectively compared on the 
basis of experts’ ratings. Nutt et al.’s findings showed no relation-
ship with the rank ordering by experts and categorisation of drugs 
under the UK Misuse of Drugs Act, and caused considerable con-
troversy within the government and media.
Subsequently we used the same harm matrix to survey over 
1500 UK drug users and found significant correlations between 
their harm rankings and those of Nutt et al.’s experts, but none 
between users’ rankings and the current classification of drugs 
under the UK Misuse of Drugs Act (Morgan et al., 2010b). These 
findings were then replicated in the Netherlands, where a two-
class classification systems is employed (van Amsterdam et al., 
2010), and a recent web-based survey of drug users (predomi-
nantly mephedrone users) which provided a very similar profile of 
rankings to the studies outlined above based on harm ratings of 13 
psychoactive substances (Carhart-Harris, 2011). Once again alco-
hol and tobacco were rated to be highly harmful whilst cannabis, 
ecstasy and magic mushrooms were rated as relatively safe. In 
response to doubts raised about the differential weighting and 
choice of criteria used, Nutt et al. (2010) used ‘multicriteria deci-
sion analysis’ to develop a weighted model, based again on ratings 
by experts. Their results supported their previous findings – again, 
there was no correlation between rated harms and UK ABC 
classification.
A debate has ensued, with some disputing whether it is logi-
cally possible to rank drugs on any single dimension of harm 
(Caulkins et al., 2011; Cohen, 2010). It is argued that no model 
would ever be perfect because ratings of harm to others and harms 
to self are neither objective nor measureable, as they will always 
be influenced by expertise and personal biases; indeed, Nutt et al. 
used a small number of experts with uncertain knowledge of drug-
related harms outside of their area of expertise (Coulson and 
Caulkins, 2012). Furthermore, the principle of combining indi-
vidual and aggregate harm measures to create a weighted total 
‘harm score’ may be flawed, in that the relationship between these 
two types of harm may not be additive. The latter authors further 
suggested that even perfect calculation of harm scores cannot 
determine how a new drug should be scheduled. Scheduling sys-
tems are interrelated with some drugs being precursors to others, 
and thus it is difficult for them to be considered on a drug-by-drug 
basis. In addition the consequences of scheduling, changes depend 
on context of use of the drug; for example, alcohol is highly harm-
ful to use whilst driving. Nutt et al. (2010) also did not take into 
account either differential availability of illegal substances or poly 
drug use. Caulkins et al. (2011) proposed alternative ‘harm matri-
ces’ which would take into account the context of drug use, so 
each substance in each context would be associated with harm-
type ratings. However, although this process would be an interest-
ing one to explore, it was deemed too lengthy and complex for an 
internet survey, and thus we adopted the Nutt et al. framework, for 
parsimony and ease of use.
Whilst drug harms may not be sufficient to determine policy 
(Kalant, 2010) the belief that policies informed by science are bet-
ter than those with no scientific basis at all has been expressed by 
several researchers (e.g. Fischer and Kendall, 2011; Obot, 2011; 
Room and Lubman, 2010). The value of informing policy makers 
of the relative harm of drugs is not opposed even by critics 
(Caulkins et al., 2011). As well as harms, however, recreational 
drugs have perceived benefits, otherwise they would not be used. 
There are a variety of historical and emerging beneficial uses of 
various compounds that are illicit substances; for example canna-
bis, once used as a sedative and anti-convulsant in the UK and US 
(Walton, 1938), has recently been explored in its organic form and 
components as an analgesic, anti-emetic and appetite stimulant. 
Renewed efforts have also been made to demonstrate the efficacy 
of illicit drugs as adjuncts to psychotherapy, either as psycholytics 
or psychedelics, with promising results (see Sessa, 2005 for a 
review). For example, in two small studies, MDMA has been 
found to be effective as an adjunct to exposure therapy for post-
traumatic stress disorder (PTSD) and therapy-resistant anxiety 
disorders (Johansen and Krebs, 2009; Mithoefer, 2006; Sessa, 
2007). In addiction treatment with single dose of LSD, in the con-
text of alcohol treatment programmes in the 1960s and 1970s, is 
associated with a decrease in alcohol misuse (Krebs and Johansen, 
2012), whilst ketamine has improved rates of abstinence in the 
treatment of heroin addicts (Krupitsky et al., 2002).
A wide literature has detailed the benefits of recreational drugs 
to users (e.g. Griffiths et al., 2006, 2008, 2011; Móró and Noreika, 
2011; Müller and Schumann, 2011; Tart 1971). However, only 
two studies to date have compared the potential benefits of illicit 
drugs to the harms (Carhart-Harris and Nutt, 2010; Morgan et al., 
2010b). The latter assessed the perceived acute and long-term 
benefits of 21 substances in over 1500 drug users whilst the for-
mer compared the benefits of four types of substances in 626 
users. Users presumably make a complex cost/benefit judgement 
when taking recreational drugs. Understanding both the harms 
and benefits of taking drugs for users is important for the uptake 
of health education, and therefore it is important to collect accu-
rate and up-to-date data on regular users’ perspectives of the ben-
efits of taking drugs.
The current study aimed to provide a more comprehensive 
account of the perceived benefits as well as harms of 18 psychoac-
tive substances (11 illicit and seven legal). As previous surveys 
have been limited to UK or the Netherlands, it also aimed to 
obtain an international sample of users with diverse cultural and 
legal approaches to psychoactive substances.
Methods
A website was designed using Web II software and was distrib-
uted internationally via a link on Erowid in three optional lan-
guages (English, Spanish and French). Participants were 
required to provide informed consent and confirm they were 
over 18 before entering the survey. Withdrawal from the survey 
was permitted at any time using a button at the bottom of the 
page, and participants were informed that in this instance their 
data would not be saved.
Psychoactive substance use was recorded first to establish 
which of the 18 drugs each participant would then be able to rate. 
The following drugs were grouped into three classes once data on 
substance use had been entered; Hallucinogens: 2-CB/ 2-CI, aya-
huasca, DMT, GHB, LSD, Mescaline/ Peyote, mushrooms, salvia 
divinorum; Amphetamines: amphetamine/methamphetamine, 
prescribed stimulants (e.g. Dexedrine, Ritalin); Opiates: heroin, 
methadone, opium (prescription analgesics were kept in their own 
separate group).
Only participants who regularly used the drugs went on to rate 
their benefits and harms, except in the case of hallucinogens 
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where all those reporting any prior use of the drugs were included 
on the assumption that few people would take hallucinogens ‘reg-
ularly’. This was an unfortunate practical consideration to limit 
the length of the survey for respondents. Because of very low 
numbers of users (less than 0.7% of the total sample), three drugs 
(crack, anabolic steroids, solvents: aromatic and aliphatic hydro-
carbons, ketones and haloalkanes such as benzene, m-xylene, eth-
ylbenzene, propylbenzene, 1,1,1-trichlorethane (TCE) and nitrites 
e.g. Poppers) were not included in the analyses.
Measures (for the full survey see 
supplementary online material)
Harms
Participants were asked to rate the harms associated with each 
drug on the basis of seven risk factors;
1. Short-term physical risk: Participants were asked to think 
about how much short-term physical risk they thought was 
associated with taking a single dose of a drug. They were 
instructed that a ‘single dose’ meant one bottle of beer, one 
ecstasy tablet or one line of coke. They were then asked 
‘when someone is under the effects of a drug how likely are 
they to cause themselves some physical damage. For exam-
ple, if someone is likely to die from an overdose this would 
be considered ‘extreme risk’, or if someone is likely to have 
an accident this would be ‘moderate risk’.’
2. Long-term physical risk: Participants were asked to rate 
how much long-term physical risk they thought would be 
associated with regular use each of the drugs.
3. Risk of injecting: Participants were asked, ‘how likely 
do you think people are to inject the following drugs?’ 
Although injection is not a harm in itself, it is an indicator 
of a higher likelihood of dependence, due to the rapid 
onset of effects and is also associated with risk of a range 
of serious secondary health outcomes, for example hepa-
titis C and HIV transmission.
4. Risk of physical dependence: this was assessed by ask-
ing the question ‘If someone takes the drugs below on a 
regular basis, what is the risk that they will become physi-
cally reliant on them and experience physical side effects 
if they stop?’.
5. Risk of psychological dependence: This was assessed 
by the question ‘what is the risk if someone takes the 
drugs below on a regular basis that they will develop 
cravings?’.
6. Risk to society: Participants were told that some drugs 
are seen to have a negative impact on society by damag-
ing family relationships, damage to property, or through 
the cost of policing. They were then asked to rate the level 
of risk to society which they thought each drug posed.
7. Risk of bingeing: Participants were asked to rate the 
likelihood of bingeing. Bingeing means the tendency to 
repeatedly dose with a substance, and is an indicator of 
the dependence-forming properties of a drug, hence it 
presence as an indicator of harm .When a person takes an 
excessive amount of a drug, for example more than 10 
units of alcohol in a single session, this is considered 
‘bingeing’.
Participants were asked to score each substance on a four-point 
scale, with 0 no risk, 1 some risk; 2 moderate risk and 3 extreme 
risk. The scores for these seven factors were averaged to give a 
mean harm score.
Benefits
Participants rated 10 benefits, defined below. Five benefits com-
prised multiple items. The number of participants who rated a 
drug as having a particular benefit was calculated as a proportion 
of the total number of participants who rated that drug.
1. Sociability (4 items; Lose inhibitions/ be more sociable, 
Feel more confident, Feel closer to people/ more empa-
thy, Feel part of a social group)
2. Enjoyment (5 items; Enhance activities, Enhance sense of 
fun/humour, Help with creativity/ abstract thinking, 
Increase sexual function/ enjoyment, Feel elated/ euphoric)
3. State of mind (6 items; Open up to new experiences, 
Altered senses, Increase existential awareness, Find 
meaning in the self and the world, Help alter conscious-
ness, To get out of my head/ escapism)
4. Pain (2 items; Relieve symptoms of disease/ illness, 
Relieve physical pain)
5. Relieve anxiety/ depression (1 item)
6. Feel more relaxed/ relieve stress (1 item)
7. Change appearance of body (bulk up/ lose weight)  
(1 item)
8. Help wake up/ have more energy (1 item)
9. Help to get to sleep (1 item)
10. Improve attention, memory and concentration  
(1 item)
Participants were also asked to report their first and second 
preference for drugs.
Finally, participants were asked to assess their own depend-
ence using four binomial yes/no questions taken from the CAGE-
AID (‘Cut-Down, Annoyed, Guilty, Eye-Opener’ Adapted to 
Include Drugs) dependence scale (Brown and Rounds, 1995) The 
CAGE-AID was developed as a time-saving screening tool for 
clinicians in primary care and whilst it cannot indicate depend-
ence, it can reflect a likelihood of abuse or dependence, warrant-
ing further screening.
The survey was launched on Erowid on the 7 March 2011 and all 
data up until 17.30 on 5 December 2011 were included in this report.
Statistical analyses
Spearman’s rank correlation coefficient was used to analyse the 
relationship between UK classifications and US scheduling of 
illicit substances and the perceived harms of psychoactive drug as 
rated by users in the UK and US.
Results
Demographics
A total of 5691 individuals, worldwide, completed the online sur-
vey. Their demographic data are displayed in Table 1.
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Number of participants who rated themselves as regular users 
of a drug and therefore rated their associated harms and benefits 
are reported in Table 2.
Harms
Table 3 presents mean harm ratings of drugs on the seven risk 
factors. Data for the overall mean harm ratings are presented in 
Figure 1. They are displayed in terms of the drug’s classification 
under (a) US schedules and (b) UK Misuse of Drugs Act as they 
represented the largest number of respondents. Amphetamines 
and prescription analgesics were excluded from the UK interpre-
tation and opiates/heroin were excluded from the US interpreta-
tion, as substances falling within these drug categories had 
different classifications or scheduling. US ratings of harms were 
not correlated with their status under the Controlled Substances 
Act schedule (Spearman’s rank correlation -0.240; p=0.41).
UK ratings also did not correlate with the legal classifications 
under the Misuse of Drugs Act, as evidenced in the lack of 
correlation between ranking of harms by users (Spearman’s rank 
correlation 0.095; p=0.76).
Benefits
Percentages of participants reporting each of the 10 benefits are 
shown in Table 4 ranked from highest to lowest percentage. Skunk 
and herbal cannabis/resin were considered overall to be the most 
beneficial drugs, followed by prescription analgesics, cocaine and 
opiates. Sildenafil (Viagra) / Tadalafil (Cialis) and hallucinogens 
were rated to be least beneficial on these scales. The mean percent-
age of participants rating each drug as a benefit compared with the 
mean harm rating of that substance is displayed in Figure 2.
Drug of choice
Drug preferences of regular users as evidenced by first and second 
‘drug of choice’ are displayed in Figure 3. First and second prefer-
ence profiles for drugs were very different. Skunk, prescription 
Table 1. Demographic data for the sample: percentage in each category.
Gender
Male Female No reply
76.2 23.5  0.4
Age
18–24 25–30 31–40 41–50 51–60 61–65 66–110 No reply
61.53 14.40 10.53  6.75  4.87  1.00  0.43  0.48
Education
Early leaver Secondary Undergraduate Post-graduate No reply
 6.04 35.73 42.95 14.28  1.00
Employment
Retired Unemployed Carer/homemaker studying Employed No reply
 2.19 13.33  2.38 39.39 41.94  0.76
Ethnicity
White African Indian East Asian Mixed Race Other No Reply
88.36  0.64  1.33  0.35  5.61  3.16  0.55
Sexual Orientation
Heterosexual Homosexual Bisexual No Reply
83.60  3.70 11.74  0.97
Religion
Christian Hindu Muslim Buddhist Jewish Agnostic/Atheist Sikh Other No reply
17.42  0.50  0.47  3.61  1.54 50.15  0.02 22.41 3.89
Country
USA UK Europe Canada Australia/ 
New Zealand
South/ Central 
America
Other No Reply
54.31 15.25 11.10  7.53  4.54  2.09  4. 59  0.59
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analgesics and opiates were rated highly as first-preference drugs, 
but were rated relatively low as second preferences. Alcohol, 
herbal cannabis and benzodiazepines showed the opposite pattern 
and were rated highly as second preference drugs but not as first 
preferences. Ecstasy showed consistently high ratings across first 
and second preferences, whilst tobacco, nitrous oxide (N2O), and 
hallucinogens were consistently ranked in the bottom 10 drugs.
Personal use and abuse of drugs
Tobacco consistently had the highest percentage of participants 
who rated themselves as showing likelihood for abuse or depend-
ence on the CAGE-AID (Table 5).
Discussion
In terms of harms, there was a lack of any correlation between the 
rankings of nearly 6000 individuals and the rankings of drugs 
within either the US Schedules or the UK Misuse of Drugs Act. 
The findings in terms of UK rankings concur with previous litera-
ture (Nutt et al., 2007, 2010; Morgan et al., 2010b) and in terms of 
the USA scheduling system are consistent with UK findings yet 
novel in this context. Over 50% of respondents were from the US, 
with the majority of users being young (18–24), white, educated 
and currently either employed or studying.
Harms
Under US scheduling, the drugs rated as most harmful were either 
classed as Schedule II or not classified, whilst several of the drugs 
rated as least harmful are currently Schedule I. Similarly in the UK, 
two currently unclassified drugs – alcohol and tobacco – were rated in 
the top 10 most harmful drugs, whilst ecstasy and hallucinogens (both 
Class A drugs) were both rated relatively low on harms. Both strains of 
cannabis were rated as the least harmful drugs despite their Class B 
status. High harm ratings appeared to be driven by perceived long-
term physical risks, risk of bingeing and craving. As expected, alcohol 
was perceived as a particularly high risk to society and had the highest 
perceived risk of bingeing, whilst risk of injecting was associated pre-
dominantly with opiate use, perhaps unsurprisingly.
Table 2. Participants’ experience of drugs.
Regular users Occasional 
users
Ex users Have 
tried it
Know someone 
who has used it
No direct experience 
/Not heard of it
Total able to 
rate harms
Alcohol 2341 2472 475 388 54 61 2341
Amphetamines 634 1236 778 2653 2794 3477 634
Benzodiazepines 335 792 294 1281 1155 1929 335
Cannabis: herbal 2863 1302 576 639 243 162 2863
Cannabis: skunk 2810 1154 518 570 262 472 2810
Cocaine 99 789 506 1617 1853 927 99
Ecstasy 336 1353 423 1332 1577 765 336
Hallucinogens 1058 5202 1018 7898 11606 25316 14587
Ketamine 106 357 106 842 1739 2641 106
Nitrous oxide 126 711 173 1592 1016 2168 12619
Mild stimulants 3187 1524 153 538 113 271 3187
Opiates 202 441 428 2168 4369 9764 202
Prescription 
analgesics
354 952 316 1783 1054 1327 354
Tobacco 2107 987 968 1058 526 145 2107
Viagra/Cialis 43 125 9 412 1071 4126 43
‘Mild Stimulants’ = caffeine, khat.
0
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2
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Schedule I
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Figure 1. Mean harm ratings of drugs against a) US Schedules under the 
Controlled Substances Act b) UK legal classifications under the Misuse 
of Drugs Act.
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Benefits
Whilst cocaine, ecstasy, mild stimulants and amphetamines were 
linked to ‘help waking up’ and ‘improving attention and memory’, 
benzodiazepines, prescription analgesics and both types of cannabis 
were associated with relaxation, decreased depression/anxiety and 
relief from pain and illness. Although our division is somewhat arbi-
trary, overall, herbal and skunk cannabis, ecstasy and ketamine were 
rated as having low harms but high benefits, and tobacco was rated 
high on harms and low on benefits. Opiates, prescription analgesics 
and cocaine showed particularly high harms and benefits. Viagra/
Cialis and hallucinogens were rated to be of relatively little benefit.
High benefits, low harms
Herbal cannabis and skunk were consistently placed in the top five 
drugs across the majority of benefits (except for ‘improving attention, 
memory and concentration’, ‘help waking up/ have more energy’ and 
‘changing appearance of body’). In addition, both strains had the high-
est percentage of participants reporting benefits of ‘enjoyment’ and 
‘relief of physical pain/ symptoms of illness or disease’, with skunk 
showing a slightly higher percentage in both instances. The two strains 
of cannabis were rated similarly for benefits, both with a primary ben-
efit of relaxation/stress relief followed by their ability to aid sleep and 
enjoyment. There was little difference between skunk and other forms 
of cannabis, which is surprising given recent debates about increased 
harms of high-THC/low-cannabidiol varieties (di Forti et al., 2009; 
Morgan et al., 2010a,c). Ecstasy was also rated highly across all ben-
efits (except for relaxation, relief from anxiety/ depression, relief of 
pain and help sleeping). MDMA was the highest ranked drug in the 
sociability category, with ‘feeling closer to people/empathy’ being the 
most often reported aspect of sociability. In contrast with both UK and 
USA classification systems, skunk and herbal cannabis were rated as 
Table 3. Mean harm ratings of drugs on each of the seven risk factors.
Short-term 
physical risk
Long-term 
physical risk
Risk of 
injecting
Risk to 
society
Risk of 
bingeing
Risk of 
reliance
Risk of 
craving
Opiates 1.3 2.1 2.4 1.8 2.3 2.5 2.7
Prescription 
analgesics
1.1 2.0 1.6 1.5 2.3 2.4 2.5
Cocaine 1.1 2.2 1.4 1.8 2.5 1.6 2.5
Alcohol 1.0 2.1 0.2 2.3 2.6 1.8 2.0
Amphetamines 1.0 1.9 1.2 1.5 2.2 1.7 2.1
Tobacco 0.9 2.4 0.1 1.1 2.0 2.3 2.6
Benzodiazepines 0.9 1.9 0.7 1.1 2.1 2.2 2.1
Ketamine 0.9 1.5 1.4 0.8 1.6 0.8 1.5
Mild stimulants 0.5 1.1 0.5 0.5 1.3 1.4 1.6
Ecstasy 0.8 1.4 0.4 0.6 1.7 0.6 1.2
Nitrous oxide 0.7 1.1 0.1 0.4 1.5 0.4 1.2
Hallucinogens 1.0 1.2 0.5 0.7 1.1 0.3 0.6
Viagra/ Cialis 0.3 0.6 0.3 0.3 0.9 0.6 0.4
Skunk cannabis 0.3 0.7 0.1 0.3 0.6 0.3 1.1
Herbal cannabis 0.3 0.7 0.1 0.3 0.6 0.3 1.0
Table 4. Ranked percentages of participant reporting each of 10 benefits.
Sociability Enjoyment State of mind Relieve pain/ illness Relieve anxiety/ depression
Ecstasy 70.6 Skunk.C 77.5 Ketamine 74.1 Skunk.C 71.4 Benzos 91.6
Alcohol 59.3 Herbal.C 77.2 Ecstasy 71.2 Herbal.C 70.7 Skunk.C 74.8
Cocaine 51.8 Ecstasy 77.0 Skunk.C 62.7 PPK 66.8 Herbal.C 74.8
Herbal.C 40.4 Cocaine 60.0 Herbal.C 62.4 Opiates 62.4 PPK 70.6
Skunk.C 40.3 Ketamine 54.0 N2O 53.8 Ketamine 40.1 Opiates 64.9
PPK 39.1 N2O 50.2 PPK 36.0 Benzos 34.0 Ketamine 61.3
Benzo 36.2 Alcohol 46.1 Cocaine 36.2 N2O 24.6 Ecstasy 60.0
Opiates 36.0 PPK 45.1 Opiates 34.2 Alcohol 24.1 Alcohol 49.2
Amphet 31.8 Amphet 41.9 Benzos 30.3 Ecstasy 21.4 Tobacco 45.7
Ketamine 28.8 Opiates 39.1 Alcohol 28.3 Cocaine 19.2 Cocaine 45.5
Mild stim 23.1 Viagra 34.0 Hallucin 27.6 Amphet 15.8 Amphet 36.6
Viagra 20.9 Mild stim 31.4 Amphet 22.9 Viagra 10.8 N2O 29.4
Tobacco 19.6 Benzos 26.5 Mild stim 13.9 Mild stim  8.3 Mild stim 22.4
N2O 15.1 Hallucin 22.5 Viagra 12.0 Tobacco  7.0 Hallucin 11.0
Hallucin 10.9 Tobacco 11.2 Tobacco  7.1 Hallucin  3.7 Viagra  9.3
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the least harmful drugs whilst ecstasy was rated as sixth least harmful. 
These low harm scores were driven by particularly low perceived risk 
of dependence, risk to society and risk of injecting.
Ketamine was ranked fifth as a drug of choice, and was ranked 
high on benefits for an individual’s state of mind, enjoyment and pain 
relief. Ketamine was ranked eighth overall in terms of harms, higher 
than the two types of cannabis and ecstasy, which appears to be a result 
of higher ratings on measures of craving, bingeing and long-term 
physical risk, concurrent with recent reports of dependence on keta-
mine (Morgan and Curran, 2011).
High benefits, high harms
Cocaine showed consistently high rankings across all benefits but 
was rated as the third most harmful drug due to high perceived 
risk of bingeing, dependence and craving as well as long-term 
physical risk. Prescription analgesics were also ranked in the top 
10 drugs across every benefit except ‘help waking up’, and were 
ranked in the top four in terms of relief from anxiety/ depression, 
stress and physical pain. As with cocaine, perceived overall harm 
of prescription analgesics was also extremely high (second most 
harmful). Opiates were rated as the most harmful drug, but were 
perceived to be highly beneficial for pain relief, alleviation of 
anxiety/ depression and stress. Whilst these drugs shared some of 
the benefits and harms of prescription analgesics, they were less 
likely to be a drug of choice, which may be due to the higher risk 
of injecting and craving associated with this group.
Benzodiazepines had the benefits of sedative and anti-
depressant/anxiolytic effects and showed similar rankings as 
opiates in terms of sociability and state of mind. Benzodiazepines 
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Figure 2. Comparison between mean percentage of participants rating each drug as a benefit and mean harm of drugs.
Feel more relaxed/ 
relieve stress
Help to get to 
sleep
Help wake up/ have 
more energy
Improve attention, memory and 
concentration
Change appearance of body 
(bulk up/ lose weight)
Benzos 95.8 Benzos 90.2 Cocaine 84.9 Amphet 66.7 Cocaine 36.4
Herbal.C 92.5 Skunk.C 78.2  Mild stim 83.7 Mild stim 63.4 Amphet 34.7
Skunk.C 91.7 Herbal.C 77.5 Amphet 67.7 Cocaine 51.5 Ecstasy 22.3
PPK 86.1 PPK 61.3 Ecstasy 53.3 Tobacco 31.9 Opiates 19.8
Tobacco 82.2 Opiates 50.5 Tobacco 39.0 PPK 28.8 PPK 17.5
Alcohol 81.5 Alcohol 43.6 PPK 31.9 Herbal.C 24.6 Tobacco 16.0
Opiates 67.3 Ketamine 17.9 Opiates 25.7 Skunk.C 23.8 Mild stim 14.8
Ketamine 66.0 N2O 16.7 Ketamine 17.0 Opiates 21.3 Viagra 11.6
Ecstasy 59.5 Tobacco 14.2 Herbal.C 14.3 Ecstasy 16.7 Herbal.C  9.2
N2O 51.6 Viagra  4.7 Skunk.C 14.0 Benzos 14.0 Ketamine  9.4
Mild stim 29.2 Amphet  3.2 Viagra  9.3 Viagra  9.3 Skunk.C  8.7
Viagra 27.9 Cocaine  2.0 Alcohol  7.3 Ketamine  8.5 Alcohol  6.2
Cocaine 25.3 Mild 
stim
 2.0 Benzos  6.3 Hallucin  5.1 Benzos  4.8
Amphet 21.1 Hallucin  1.8 N2O  4.8 Alcohol  1.4 Hallucin  1.3
Hallucin 11.6 Ecstasy  1.5 Hallucin  4.3 N2O  0.8 N2O  1.2
Herbal.C: herbal cannabis; Skunk.C: skunk cannabis; PPK: prescription painkillers (prescription analgesics); Benzo: benzodiazepines; Amphet: amphetamine; Mild stim: 
mild stimulants; N2O: nitrous oxide; Hallucin: hallucinogens.
Table 4. (Continued)
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were rated as considerably less harmful than opiates; in this 
respect, the perceptions of these drugs concurs with their legal 
status. The high preference for prescription analgesics and ben-
zodiazepines by regular users is a profile that has not been 
reported in any other study and may indicate a relatively unu-
sual sample, or may reflect the recent trend towards prescrip-
tion drug use in the US.
Low benefits, high harms
Tobacco was consistently ranked in the bottom three drugs in 
terms of benefits, with the exception of relieving anxiety/ depres-
sion or feeling more relaxed/ relieving stress. Whilst tobacco was 
ranked seventh in overall harms, this drug was unsurprisingly 
associated with high long-term physical risk and risk of reliance. 
Tobacco had the highest proportion of likely dependent users as 
classified by the CAGE.
Amphetamines and alcohol were rated to be of medium bene-
fit. Both were rated as drugs with high risk of bingeing and crav-
ing, but amphetamines scored highly on benefits of stimulant 
effects such as waking up/ having more energy, changing appear-
ance of the body and were ranked as the most beneficial drugs in 
terms of improving attention, memory and concentration. Alcohol 
was thought to be highly beneficial for sociability. It was ranked 
fifth in terms of harms, with particularly high risk to society and 
risk of bingeing.
Low benefits, low harms
Drugs that were rated as having low harms and low benefits were 
Viagra, hallucinogens, nitrous oxide and mild stimulants. The low 
beneficial rating of hallucinogens contradicts the findings of our 
prior UK drug survey (Morgan et al., 2010b). where hallucino-
gens were rated as one of the drugs with greatest long-term bene-
fits. Hallucinogens were the least preferred drug, which may 
reflect the inclusion of a wider group of users compared with all 
other substances, and along with Viagra/cialis were ranked in the 
bottom five on all benefits. This is perhaps surprising given 
the use of Viagra/Cialis as a medicine and previous reports of the 
positively beneficial effects of hallucinogens (e.g. Griffiths et al., 
2006, 2008); this may, however, reflect the very specific benefits 
of these substances which are not reflected in a mean overall ben-
efits rating on the scale used in this study.
Abuse and dependence
The USA scheduling system is based on the potential for abuse 
of each substance, hence one might expect it to be mirrored in 
the proportion of individuals scoring in the abuse range of the 
CAGE-AID for the different drugs included in this survey. 
However, in the present study tobacco had the highest propor-
tion of regular users showing possible abuse or dependence, 
followed by opiates, prescription analgesics, cocaine and 
alcohol. Thus three drugs in the UK and two in the US which 
are currently unclassified produce the greatest likelihood of 
abuse or dependence, albeit on a crude scale. Indeed, in the 
case of prescription analgesics, opiates, cocaine and alcohol, 
the overall high harm ratings obtained tended to result from 
high risks of reliance and craving, whilst tobacco scored par-
ticularly high in terms of reliance. Furthermore, ecstasy and 
hallucinogens, currently Class A and Schedule I, were scored 
low in the proportion of regular users showing possible abuse 
on the CAGE-AID.
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Figure 3. Percentage of participants reporting each drug as a) first 
preference b) second preference.
Table 5. Ranked percentage of participants using each substance who 
responded ‘yes’ to two or more CAGE questions.
CAGE score ≥2 (%)
Tobacco 93.2
Prescribed analgesics 75.7
Cocaine 69.7
Opiates 63.4
Cannabis- skunk 63.3
Alcohol 61.7
Cannabis - herbal/resin 61.1
Benzodiazepines 57.9
Ketamine 52.8
Mild stimulant 43.6
Amphetamines 43.2
Ecstasy 42.0
Nitrous oxide 21.0
Viagra/ Cialis 17.1
Hallucinogens  6.9
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Limitations
As an internet survey, it was not possible to verify that each respond-
ent was unique, and the sample was inevitably self-selecting. Of the 
nearly 6000 individuals who completed the survey, the majority 
were well educated, white, employed or studying. The survey was 
only translated into English, Spanish and French, and this may 
have reduced the number of respondents from many countries 
where other languages predominate. At the same time, this is the 
first multi-language survey of drug users to date with the largest 
number of respondents who were spread across 61 countries 
worldwide.
A further limitation of the current study is that the harms and 
benefits of polysubstance use, which is becoming the norm 
amongst the vast majority of drug users, were not addressed. This 
was beyond the scope of this study and it would be have been a 
complex task for drug users to rate the effects of multiple sub-
stances. Further, research suggests that drug users are aware of the 
key effects of the drugs they take, even novel compounds such as 
mephedrone (Carhart-Harris, 2011), despite being taken in combi-
nation with other substances. However, future work should aim to 
explore this interesting issue. Similarly, the study could not assess 
the context dependence of the benefits or harms or the benefits of 
the drug effects versus drug culture, for example the benefits of 
the sociable dance music culture that can occur around ecstasy 
use. This study also did not distinguish between what were bene-
fits of acute drug effects and longer-term benefits (although we 
attempted this in our previous UK drug survey, Morgan et al., 
2010b). In future work, we would aim to compare harms and ben-
efits on similar scales, and take into account context effects.
Another limitation was that the number of users rating on hal-
lucinogens was much greater than for other substances because, 
as there are no ‘regular’ users, this included people who had ever 
tried any of a wide range of hallucinogens. For all other drugs, 
harms and benefits could only be rated by those who judged 
themselves regular users and so data for hallucinogens were com-
paratively skewed. Thirdly, there were low numbers rating some 
drugs (e.g. crack) and we did not explore the use of different 
drugs in combination, mainly to restrict the length of the survey 
so as to increase completion rates. Only regular users of each 
drug were allowed to rate its benefits and harms in the current 
study, thus drug benefits may be perceived to be greater than if a 
sample of ex- or non-users were used. Regular users may down-
play risks in their continued use of these substances, much as a 
car driver plays down the risk of road traffic accidents. Therefore 
it could be argued that users are not the best people to rate on 
harms. However, in our previous study of drug users’ views of 
harms (Morgan et al., 2010b) we found a very high correlation 
between ‘expert’ and user ratings of harm, therefore it would 
seem that even if users downplay the risks in their own behav-
iour, or simply weight the benefits greater than the potential 
costs, this would not appear to substantially diminish their aware-
ness of the severity of the harms. Further, this sample is unique in 
its ability to provide extensive knowledge of drug effects, par-
ticularly benefits, across a range of psychoactive substances. 
Given that the literature on drug use has been dominated by 
research into harms, taking into account the views of these users 
– even if they might be skewed towards more positive percep-
tions of recreational drugs – is important if we are to converge on 
a more balanced position on illicit substance use.
Implications
Our survey expanded upon that of Nutt et al. (2007, 2010) by 
including a detailed assessment of the perceived benefits of drugs. 
A full scientific understanding of the relative harms and benefits 
of recreational drugs is important. In understanding the perceived 
benefits of illicit substances we may learn about the motivation 
behind their use, which can prove useful in developing treatment 
programmes. The lack of correlation between the users’ ranked 
harms and drug classifications in the UK and USA suggest that 
current drug policy is not serving to inform those who take drugs 
of the harms of these substances. Furthermore, the prevalence of 
use of each substance within this sample suggests that current 
policy does not influence whether people choose to use the drug. 
For example, herbal cannabis and skunk, currently Class B in the 
UK and Schedule I in the USA, were respectively the second and 
third most regularly used drugs.
The high benefits and low harms of skunk, herbal cannabis and 
ecstasy do not correspond with their current legal classifications. 
Further, alcohol and several prescription analgesic drugs are cur-
rently not classified in the UK, e.g. Tramadol, but were rated high 
in harm, whereas in the USA all prescription analgesics have been 
classified as Schedule II. Whilst these results might be taken to 
imply that prescription analgesic drugs should be placed in the 
highest class or schedule, these drugs were also rated as having a 
wide variety of benefits. Although a system based entirely on drug 
harms has been suggested to be unworkable (Caulkins et al., 
2011), it would seem prudent to produce a full assessment of the 
relative harms and benefits of psychoactive substances – which 
perhaps this preliminary study may in some way inform – so that 
policy makers may more accurately take into account the relative 
harms and benefits when deciding how to control these sub-
stances. Whilst these data, which are simply the opinions of drug 
users, may not serve to inform policy, they can inform us of the 
views of drug users on the perceived benefits and harms of psy-
choactive substances, which may be important for effective drugs 
education and treatment.
Conclusion
In summary, there are very marked disparities between the rated 
harms of different drugs by nearly 6000 users and the rankings of 
these drugs in both UK and USA classification systems. In par-
ticular the classification of skunk, herbal cannabis/resin and 
ecstasy appears arbitrary not only in terms of rated harms but also 
ranked benefits, preference and dependence. Currently unclassi-
fied drugs (alcohol and prescription analgesics (UK)) had high 
ratings of harms but also relatively high ranking of benefits and 
high preference. It is therefore important to consider both the per-
ceived consequences and motivations for drug use to better inform 
both policy and educational programmes.
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